Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label gabapentin extension in pediatric partial seizures
2014-004175-23Phase 3
- Sponsor
- Pfizer
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gabapentin in epilepsy, sponsored by Pfizer. Primary endpoint: Number of subjects with treatment-emergent adverse events (all causalities and treatment-related).
02
Drugs
gabapentin
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2014-004175-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004175-23.